Viromed Medical AG, a medical technology company specializing in cold plasma technology, announced the appointment of Prof. Dr. Michael A. Rubhausen to its Medical Advisory Board, effective immediately. The physicist, known for his work in modern spectroscopy and materials research, will contribute his scientific expertise to the company's research initiatives, particularly at the intersection of material properties, spectroscopy, and cold plasma.
CEO Uwe Perbandt expressed confidence in the new appointment, stating that Prof. Rubhausen's proven expertise will help the company thoroughly evaluate scientific questions and support its ongoing research work. The appointment comes as Viromed seeks to advance the application of cold plasma technology in medicine and capitalize on its growth potential.
Prof. Rubhausen currently heads the Optics Working Group at the Institute of Nanostructure and Solid-State Physics at Universität Hamburg, where he also serves as Managing Director. He is affiliated with the Center for Free-Electron Laser Science (CFEL). His research utilizes advanced spectroscopic methods, including Raman spectroscopy and ellipsometry, to study a wide range of materials, from superconductors to biological samples. His work is conducted at large-scale research facilities such as PETRA III and FLASH, highlighting his involvement in cutting-edge scientific inquiry.
With over 180 publications and approximately 4,000 citations, Prof. Rubhausen's contributions have appeared in prestigious journals such as Physical Review Letters, Nature Chemistry, and Nature Physics. His interdisciplinary approach also includes the development of AI-supported analysis workflows for complex datasets, a skill set that could prove valuable in analyzing the intricate interactions involved in cold plasma applications.
Viromed Medical AG, listed on the stock exchange since October 2022, focuses on the development, manufacture, and distribution of medical products. Its operating subsidiary, Viromed Medical GmbH, markets innovative cold plasma technology for medical applications across the DACH region and beyond. The company aims to further integrate cold plasma into medical practice, and the addition of Prof. Rubhausen to its advisory board underscores its commitment to rigorous scientific evaluation and innovation.
The appointment of a physicist with deep expertise in spectroscopy and materials science signals Viromed's intention to explore the fundamental mechanisms of cold plasma and its effects on biological materials. This could lead to enhanced product efficacy and new applications in medicine. By strengthening its scientific advisory capabilities, Viromed is positioning itself to navigate the complexities of medical technology development and maintain a competitive edge in the evolving field of cold plasma therapy.
For more information about Viromed Medical AG, visit their website. The original press release can be viewed on NewMediaWire.
